Healthcare CEO Compensation Across Pharma, Medtech and Providers

One label, three markets

"Healthcare" is among the least useful sector labels in compensation analysis, because it covers organizations with almost nothing in common operationally or financially.

A pharmaceutical company runs long, capital-intensive R&D cycles against binary regulatory outcomes. A medical-device manufacturer runs shorter product cycles with a commercial-execution emphasis. A hospital or provider organization runs a labor-intensive service business under reimbursement pressure — and, very often, as a tax-exempt entity that files no proxy statement at all.

Those are three different labor markets for chief executives. Building a peer set that mixes them produces a range wide enough to justify almost any number, which is the practical definition of a useless benchmark.

The disclosure split that catches people out

Before sub-segment, there is a more basic division: which disclosure regime the organization falls under.

Public pharmaceutical, biotech, and device companies file DEF 14A proxy statements and disclose executive compensation under the same rules as any other public company. Nonprofit hospital systems, health plans, and academic medical centers file Form 990 instead, disclosing compensation through Schedule J.

This matters more in healthcare than in almost any other sector, because a large share of provider organizations are tax-exempt. A meaningful portion of the sector's senior roles are disclosed on a completely different instrument, on a different timetable, with different components.

The two cannot be pooled without adjustment. A 990 total is cash and benefits, with no equity component to speak of. A proxy total is frequently dominated by grant-date equity valuations. Placing them in the same distribution and reading a median produces a figure that describes neither group.

How the sub-segments differ structurally

Pharmaceutical and biotech. Long development timelines and binary outcomes push toward equity weighting and toward performance conditions tied to development milestones rather than to a single fiscal year. Clinical-stage companies with no revenue at all are a distinct case again — their compensation structure resembles the growth-stage technology pattern more than it resembles a large pharmaceutical company's.

Medical devices. Shorter product cycles, an approval pathway that differs from drug approval, and a heavier commercial-execution emphasis. Pay tends to sit between the pharmaceutical pattern and a conventional industrial manufacturer's.

Providers and health systems. Predominantly nonprofit, so predominantly cash and benefits. Incentive structures, where they exist, are frequently tied to quality and operational measures rather than to financial return, reflecting both the mission and the absence of shareholders.

Health insurers and managed-care organizations are a fourth group again, some public and some nonprofit, and they generally do not belong in a peer set with either drug developers or hospital systems.

Regulatory environment as a compensation variable

Healthcare carries a compliance dimension that shapes pay structure in ways most sectors do not.

For tax-exempt organizations, executive compensation is subject to scrutiny that has no direct corporate analogue, and boards commonly document a deliberate process for setting it — including reliance on comparability data. That is one reason nonprofit healthcare compensation decisions tend to be accompanied by an explicit peer analysis: the documentation is part of the point.

The practical implication for anyone building a comparison is that the standard is not just "is this number reasonable" but "can the process that produced it be shown." A sourced, checkable peer file is not a nicety in this sector; it is closer to the expected form.

Building a peer set that survives challenge

Four screens, applied in order.

• Disclosure regime. Decide whether you are comparing proxy filers or 990 filers. If the role genuinely spans both, run two separate comparisons and present them separately rather than merging them.
• Sub-segment. Pharma, biotech, device, provider, or payer. Do not mix.
• Size band. Revenue for commercial organizations, total expenses for nonprofits — and note that these are not the same measure, which is another reason not to pool the two groups.
• Development stage, for pharma and biotech specifically. A commercial-stage company and a clinical-stage one are not peers.

Geography matters for provider organizations more than for the others, since provider labor markets and reimbursement environments are regional in a way that drug development is not.

Normalizing across the two regimes

If you must characterize the whole sector, normalize deliberately and say what you did.

For proxy filers, note that equity is reported at grant-date fair value and consider reading the pay-versus-performance figures alongside it. For 990 filers, follow the Schedule J normalization steps — align tax years, identify one-time amounts in other reportable compensation, aggregate across related organizations, and check the previously-reported column. Related-organization aggregation is especially important in healthcare, where executives are frequently paid across a parent system, an affiliated foundation, and a physician group.

Then compare cash to cash. Total-to-total comparison across the two regimes is not meaningful; base-plus-bonus against base-plus-bonus is at least measuring a comparable thing, provided you say that equity is excluded and why.

Payers and managed care are their own category

Health insurers and managed-care organizations sit inside the healthcare label and belong in neither the drug-development nor the provider peer group.

Their economics are closer to financial services than to either: they manage risk pools, hold reserves, and operate under insurance regulation as well as healthcare regulation. Large public insurers file proxies and disclose compensation like any public company. Nonprofit health plans — including a number of substantial regional plans — file Form 990 instead, which puts the same sub-segment on both sides of the disclosure divide.

For anyone building a comparison in this space, the practical instruction is to treat payers as a distinct fourth group, and to check the disclosure regime organization by organization rather than assuming it from the name.

What the clinical-stage case does to a benchmark

Biotech deserves separate handling because a clinical-stage company is not a smaller version of a commercial one.

A company with no approved product and no revenue is valued on pipeline probability. Its chief executive is running a research and financing operation rather than a commercial business, and compensation is structured accordingly — typically equity-heavy, frequently with milestone conditions tied to trial phases or regulatory submissions rather than to financial results.

Sizing such a company by revenue fails immediately, since revenue is zero. The workable size proxies are market capitalization, cash position, or headcount, and whichever you choose should be stated. A peer set that sizes commercial companies by revenue and clinical-stage companies by market cap is not internally consistent, and the inconsistency should be disclosed rather than buried.

Quality and mission measures in provider incentive design

Where provider organizations do operate incentive plans, the measures frequently differ from anything a corporate plan would use.

Patient outcomes, safety indicators, access and community-benefit measures, and workforce metrics all appear alongside — or instead of — financial targets. For a tax-exempt organization there are no shareholders, so total shareholder return is not available as a measure even in principle, and the plan has to be built on something else.

This matters for comparison in a specific way. A provider executive's incentive opportunity is not directly comparable to a corporate executive's even at the same dollar value, because the conditions attached differ in kind. Recording what the incentive was for, not just what it paid, is what makes a cross-segment observation interpretable later.

Assembling the two-regime file

When a role genuinely spans both regimes — a health-system executive whose plausible next role is at a public company, say — run the comparison twice rather than once.

Build a Form 990 peer set for the nonprofit provider comparison and a proxy peer set for the public comparison. Present them side by side as two distributions with their own labels, sample sizes, and citation types. Note explicitly that the proxy totals include grant-date equity valuations and the 990 totals do not.

Two clearly labelled distributions answer more questions than one merged figure, and they do not create the false impression of a single market that does not exist.

What to record

For each peer: the organization, the sub-segment, the size measure, the disclosure regime, the compensation components separately, and the citation — accession number and filing date for a proxy, EIN and tax year for a 990.

The citation discipline does the same work here it does everywhere else, with one addition specific to this sector: because healthcare spans two disclosure regimes, recording which regime each figure came from is what stops a comparison quietly drifting into an apples-to-oranges median that nobody can later reconstruct.

For the proxy-filing side of the sector, the Healthcare CEO Pay Comparables Guide & Peer Workbook (SEC + Form 990) shows where pharma, medtech and provider comparables are disclosed and computes percentile bands over the peers you enter, each cited to its filing. For nonprofit health systems reporting on the 990, the Nonprofit ED Total-Compensation Normalization Workbook brings their Schedule J figures to a comparable total.